Form D · Biotechnology

Interius BioTherapeutics, Inc.

Philadelphia, PA · CIK 0001807811

Offering snapshot reported Jun 3, 2024 · SEC filing

Reported sold
$51.4M
Offering amount: $82.5M
Investors reported
12
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 21, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 3, 2024Initial$51,432,536No comparison12SEC filing
Oct 20, 2023Initial$21,451,331No comparison13SEC filing
May 27, 2021Initial$43,625,657No comparisonNot reportedSEC filing
Mar 27, 2020Initial$1,575,000No comparison5SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-514940

Source: Form D, filed Jun 3, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Bihua Chen Director
Lori Forrest Executive
Saar Gill Executive
Philip R. Johnson Director, Executive
Philip R. Johnson, M.D. Director, Executive
Tomas Kiselak Director
Benjamin Lund Director
Dora Mitchell Executive
Leon O. Moulder Director
Leon Moulder, Jr. Director
Bruce Peacock Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3401 Grays Ferry Avenue Building 200, Suite 300
Philadelphia, PA, 19146